Market Place
Market Place
Post Enquiry
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Compliance troubles emerge at Pfizer, Teva, Wockhardt and Xiamen Origin
It has been an
unprecedented week where compliance glitches have emerged from almost all parts
of t
